Patents by Inventor Raymond G. Goodwin

Raymond G. Goodwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of use of the TACI/TACI-L interaction
    Publication number: 20030165986
    Abstract: The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the antagonists and agonists as therapeutics to treat autoimmune diseases, inflammation, and to inhibit graft vs. host rejections is further disclosed.
    Type: Application
    Filed: May 14, 2001
    Publication date: September 4, 2003
    Applicant: Immunex Corporation
    Inventors: Raymond G. Goodwin, Wanwan S. Din
  • Antibodies which specifically bind to TNF-R
    Publication number: 20030165459
    Abstract: Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
    Type: Application
    Filed: April 23, 2003
    Publication date: September 4, 2003
    Applicant: IMMUNEX CORPORATION
    Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
  • Method for suppressing inflammatory responses by administering TNFR
    Patent number: 6572852
    Abstract: Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: June 3, 2003
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
  • Viral proteins capable of binding LAR
    Publication number: 20030049609
    Abstract: A poxvirus protein designated A41L binds to leukocyte common-antigen-related protein (LAR). A41L is a secreted protein that can be purified from the culture supernatant of cells infected with certain poxviruses, or produced using recombinant DNA techniques. A41L polypeptides and LAR polypeptides, and nucleic acids encoding them, are provided herein. Also provided are methods of using such polypeptides and nucleic acids.
    Type: Application
    Filed: July 3, 2002
    Publication date: March 13, 2003
    Inventors: Craig A. Smith, Raymond G. Goodwin
  • Antibodies directed against trail
    Patent number: 6521228
    Abstract: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: February 18, 2003
    Assignee: Immunex Corporation
    Inventors: Steven R. Wiley, Raymond G. Goodwin
  • METHODS OF USE OF THE TACI/TACI-L INTERACTION
    Publication number: 20030022233
    Abstract: The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the antagonists and agonists as therapeutics to treat autoimmune diseases, inflammation, and to inhibit graft vs. host rejections is further disclosed.
    Type: Application
    Filed: April 30, 1999
    Publication date: January 30, 2003
    Inventors: RAYMOND G. GOODWIN, WANWAN S. DIN
  • Cytokine designated 4-1BB ligand antibodies and human receptor that binds thereto
    Patent number: 6355779
    Abstract: Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.
    Type: Grant
    Filed: September 10, 1998
    Date of Patent: March 12, 2002
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Mark R. Alderson
  • Tumor Necrosis factor-alpha and -beta receptors
    Publication number: 20020006391
    Abstract: Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
    Type: Application
    Filed: January 12, 2001
    Publication date: January 17, 2002
    Inventors: Graig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
  • Cytokine that induces apoptosis
    Patent number: 6284236
    Abstract: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.
    Type: Grant
    Filed: May 26, 1999
    Date of Patent: September 4, 2001
    Assignee: Immunex Corporation
    Inventors: Steven R. Wiley, Raymond G. Goodwin
  • Tumor necrosis factor-&agr; and -&bgr; receptors
    Patent number: 6224867
    Abstract: Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: October 17, 1997
    Date of Patent: May 1, 2001
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
  • Tumor necrosis factor receptor polypeptides recombinant P75 (Type II)
    Patent number: 6201105
    Abstract: Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: March 13, 2001
    Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
  • Use of interleukin-7 to stimulate proliferation of hematopoietic cell precursors
    Patent number: 6156301
    Abstract: Mammalian Interleukin-7 proteins (IL-7s), DNAs and expression vectors encoding mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.
    Type: Grant
    Filed: May 12, 1999
    Date of Patent: December 5, 2000
    Assignee: Sanofi-Synthelabo
    Inventors: Anthony E. Namen, Raymond G. Goodwin, Stephen D. Lupton, Diane Y. Mochizuki
  • CD30 ligand oligomers and polypeptides
    Patent number: 6143869
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Grant
    Filed: May 15, 1998
    Date of Patent: November 7, 2000
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
  • Use of interleukin-7 to stimulate proliferation of hematopoietic cell precursors
    Patent number: 5965122
    Abstract: Mammalian Interleukin-7 proteins (IL-7s)g DNAs and expression vectors encoding mammalian IL-7s, end processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: October 12, 1999
    Assignee: SANOFI
    Inventors: Anthony E. Namen, Raymond G. Goodwin, Stephen D. Lupton, Diane Y. Mochizuki
  • Purified p75 (type II) tumor necrosis factor receptor polypeptides
    Patent number: 5945397
    Abstract: Human tumor necrosis factor receptor proteins having the of amino acids 1-235 are disclosed in SEQ ID NO:2. TNF receptor deletion variants having the sequence of amino acids 1-185 or 1-163 of SEQ ID NO:2 also display TNF bing activity. Murine TNF receptor proteins are also disclosed in SEQ ID NO:4 and are capable of binding TNF.
    Type: Grant
    Filed: May 16, 1996
    Date of Patent: August 31, 1999
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
  • Cytokine which is a ligand for OX40
    Patent number: 5783665
    Abstract: There is disclosed a polypeptide (OX40-L) and DNA sequences, vectors and transformed host cells useful in providing OX40-L polypeptides. More particularly, this invention provides isolated murine OX40-L polypeptides that bind to the extracellular binding region of OX40.
    Type: Grant
    Filed: June 22, 1995
    Date of Patent: July 21, 1998
    Assignee: Immunex Corporation
    Inventors: Peter R. Baum, William C. Fanslow, III, Richard B. Gayle, Raymond G. Goodwin
  • DNA encoding a cytokine that induces apoptosis
    Patent number: 5763223
    Abstract: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.
    Type: Grant
    Filed: June 25, 1996
    Date of Patent: June 9, 1998
    Assignee: Immunex Corporation
    Inventors: Steven R. Wiley, Raymond G. Goodwin
  • CD30 ligand conjugates
    Patent number: 5753203
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides and oligomers find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Grant
    Filed: December 20, 1995
    Date of Patent: May 19, 1998
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
  • Antibodies that are immunoreactive with interleukin-7
    Patent number: 5714585
    Abstract: Antibodies that are immunoreactive with interleukin-7 (IL-7) proteins are provided. The anti-IL-7 antibodies may be polyclonal or monoclonal. Certain embodiments are directed to antibodies that are immunoreactive with human IL-7.
    Type: Grant
    Filed: April 21, 1994
    Date of Patent: February 3, 1998
    Assignee: Sterling Winthrop, Inc.
    Inventors: Anthony E. Namen, Raymond G. Goodwin, Stephen D. Lupton, Diane Y. Mochizuki
  • DNA encoding tumor necrosis factor-.alpha. and -.beta. receptors
    Patent number: RE36755
    Abstract: Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: August 31, 1998
    Date of Patent: June 27, 2000
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann